Loading
Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma.
Pieter Sonneveld was principal investigator of PERSEUS, the trial showing daratumumab added to bortezomib-lenalidomide-dexamethasone before and after transplant improves progression-free survival and MRD negativity in newly diagnosed myeloma, and led the HOVON-65/GMMG-HD4 trial that established bortezomib in induction. He chairs the European Myeloma Network and has led HOVON myeloma trials for three decades.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tags myeloma, transplant.
Shares CD38, MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.